Wedbush Upgrades Generation Bio to Outperform, Lowers Price Target to $5.5

Benzinga · 1d ago
Wedbush analyst David Nierengarten upgrades Generation Bio (NASDAQ:GBIO) from Neutral to Outperform and lowers the price target from $7 to $5.5.